Across jurisdictions, pharmaceutical companies are navigating recent changes in patent laws. Finnegan attorneys Sanya Sukduang and Emily R. Gabranski spoke with Asia IP on the ever-increasing complexity of patents in the life sciences field and what constitutes patentable subject matter, particularly in the biotechnology sector.
Commentary
November 24, 2023
Commentary
How I Made It to Law Firm Leadership: 'Devote Time to Initiatives That Improve the Firm'
November 13, 2023
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.